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Abstract. During the last twenty years there have been considerable
methodological developments in the design and analysis of Phase 1,
Phase 2 and Phase 1/2 dose-finding studies. Many of these develop-
ments are related to the continual reassessment method (CRM), first
introduced by O’Quigley, Pepe and Fisher (1990). CRM models have
proven themselves to be of practical use and, in this discussion, we in-
vestigate the basic approach, some connections to other methods, some
generalizations, as well as further applications of the model. We obtain
some new results which can provide guidance in practice.
Key words and phrases: Bayesian methods, clinical trial, continual re-
assessment method, dose escalation, dose-finding studies, efficacy, max-
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1. INTRODUCTION
The continual reassessment method (CRM) was
introduced by O’Quigley, Pepe and Fisher (1990) as
a design with which to carry out and analyze dose-
finding studies in oncology. The purpose of these
studies, usually referred to as Phase 1 trials of a
new therapeutic agent, is to estimate the maximum
tolerated dose (MTD) to be used in Phase 2 and
Phase 3 trials. O’Quigley, Pepe and Fisher (1990)
pointed out that standard methods in use then, and
still in use now, fail to address the basic ethical
requirements of experimentation with human sub-
jects. Given the unknown or poorly understood re-
lationship between dose and the probability of unde-
sirable side effects (toxicity), it is inevitable, during
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experimentation, that some patients will be treated
at too toxic doses and some patients will be treated
at doses too low to have any real chance of procur-
ing benefit. Aside from being inefficient, the case
against the standard designs is that more patients
than necessary are treated in this way, either at too
toxic a dose or, more usually, at too low a dose to
provide therapeutic benefit.
The rationale of the CRM is to concentrate as
many patients as we can on doses at, or close to,
the MTD. Doing so can provide an efficient esti-
mate of the MTD while maximizing the number of
patients in the study treated at doses with poten-
tial therapeutic benefit but without undue risk of
toxicity. A drawback of concentrating patients to
a small number of dose levels, at and around the
MTD, is that the overall dose-toxicity curve itself
may be difficult to estimate. In practice, this tends
not to be a serious drawback, since estimation of
the entire dose-toxicity curve is rarely the goal of a
dose-finding clinical trial.
Phase 1 trials evaluating the toxicity of single agents
are becoming less common, giving way to more com-
plex studies involving multiple agents at various doses,
heterogeneous groups of patients, and evaluations
of both toxicity and efficacy. The standard methods
are ill-equipped to handle these more complex sit-
uations, and here, we will discuss developments of
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the CRM and related methods for tackling various
problems which arise in the context of dose finding.
Whereas the standard method, even for the sim-
plest situation fails to perform adequately, model
based designs, while offering greatly improved per-
formance for the simplest case, allow us to take on
board those more involved situations that arise in
practice (Braun, 2002; Faries, 2004; Goodman, Za-
hurak and Piantadosi, 1995; Legedeza and Ibrahim,
2002; Mahmood, 2001; O’Quigley, 2002a; O’Quigley
and Paoletti, 2003; O’Quigley and Reiner, 1998;
O’Quigley, Shen and Gamst, 1999; Piantadosi and
Liu, 1996).
We begin with the definitions and notation used
in Phase 1 trials and an overview of the CRM as
originally proposed by O’Quigley, Pepe and Fisher
(1990). The next two sections outline Bayesian and
likelihood-based inference for the CRM, providing
results for the small-sample and large-sample prop-
erties of the method. Section 5 gives extensions of
the method and discusses modifications of the basic
design. Section 6 presents related designs, again for
the case of a single outcome whereas Section 7 con-
siders two outcomes, one positive and one negative
and describes the goal of locating the most success-
ful dose (MSD). The article concludes with a discus-
sion of future directions in the study of model-based
methods for dose-finding studies.
1.1 Doses, DLT, MTD and the MSD
Traditional thinking in the area of cytotoxic anti-
cancer treatments is to give as strong a treatment as
we can without incurring too much toxicity. For the
great majority of new cancer treatments—recent ad-
vances in immunotherapy being possible exceptions—
we consider that increases in dose correspond to in-
creases in both the number of patients who will ex-
perience toxic side effects as well as the numbers
who may benefit from treatment. If we observe a
complete absence of toxic side effects, then we would
not anticipate observing any therapeutic effect, ei-
ther for those patients in the study or for future
patients. The Phase I trial then has for its goal the
determination of some dose having an “acceptable”
rate of toxicity. While it is true that the essential
goal of the study is to improve treatment for future
patients, ethical concerns dictate that we give the
best possible treatment to the patients participating
in the Phase I study itself. The highest dose level at
which patients can be treated and where the rate of
toxicity is deemed to be still acceptable is known as
the MTD (maximal tolerated dose).
On an individual level we can imagine being able
to increase the dose without encountering the toxic
effect of interest. At some threshold the individual
will suffer a toxicity. An assumed model is the fol-
lowing: at this threshold the individual suffers a tox-
icity and, for all higher doses, the individual would
also have encountered a toxicity. Such a model is rea-
sonable for most situations and widely assumed. It
remains nonetheless a model and might be brought
under scrutiny in particular cases. The model stipu-
lates that for all levels below the threshold, the indi-
vidual would not suffer any toxicity and we call the
threshold itself the individual’s own maximum tol-
erated dose (MTD). A dose-limiting toxicity (DLT)
curve for the individual would be a (0,1) step func-
tion, the value 0 indicating no toxicity and the value
1 a toxicity. Thus, in the case of an individual, the
(0,1) step function for the DLT coincides with that
for the MTD.
Any population of interest can be viewed as be-
ing composed of individuals each having their own
particular MTD. Corresponding to each individual
MTD we have a (0,1) step function for the individ-
ual’s DLT. Over some set or population of individu-
als, the sum of the DLT curves at any dose equates
to the probability of toxicity at that same dose. For
a population we fix some percentile so that, 100×θ%
say, have their own threshold at or below this level.
The term MTD is often used somewhat loosely, and
not always well defined. The more precise definition
given in terms of a percentile involves θ. Different
values of θ would correspond to different definitions
of the MTD. The values 0.2, 0.25 and 0.33 are quite
common in practice.
When information on efficacy, possibly through
surrogate measures or otherwise through some mea-
sure of response, is available in a timely way, then
it makes sense to make use of such information. In
the HIV setting, there have been attempts to si-
multaneously address the problems of both toxicity
and efficacy. The goal then becomes not one of find-
ing the maximum tolerated dose but, rather, one of
finding the MSD (most successful dose), that is, that
dose where the probability of treatment failure, be
it due to excessive toxicity or to insufficient evidence
of treatment efficacy, is a minimum. The CRM can
be readily adapted to address these kinds of ques-
tions (O’Quigley, Hughes and Fenton, 2001; Zohar
and O’Quigley, 2006a).
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1.2 Notation
We assume that we have available k doses; d1, . . . ,
dk, possibly multidimensional and ordered in terms
of the probabilities, R(di), for toxicity at each of the
levels, that is, R(di) < R(dj) whenever i < j. The
MTD is denoted d0 and is taken to be one of the
values in the set {d1, . . . , dk}. It is the dose that has
an associated probability of toxicity, R(d0), as close
as we can get to some target “acceptable” toxicity
rate θ. Specifically we define d0 ∈ {d1, . . . , dk} such
that
|R(d0)− θ|
(1)
< |R(dℓ)− θ|, ℓ= 1, . . . , k;dℓ 6= d0.
The binary indicator Yj takes the value 1 in the
case of a toxic response for the jth entered subject
(j = 1, . . . , n) and 0 otherwise. The dose for the jth
entered subject, Xj , is viewed as random taking val-
ues xj ∈ {d1, . . . , dk}; j = 1, . . . , n. Thus we can write
Pr(Yj = 1|Xj = xj) =R(xj).
Little is known about R(·) and, given the n observa-
tions, the main goal is to identify d0. Estimation of
all or part of R(dℓ), ℓ= 1, . . . , k, is only of indirect
interest in as much as it may help provide informa-
tion on d0.
There is an extensive literature on problems sim-
ilar to that just described. The solutions to these
problems, however, are mostly inapplicable in view
of ethical constraints involved in treating human
subjects. The patients included in the Phase I de-
sign must, themselves, be treated “optimally,” the
notion optimal now implying for these patients a re-
quirement to treat at the best dose level, taken to
be the one as close as we can get to d0. We then
have two statistical goals: (1) estimate d0 consis-
tently and efficiently and, (2) during the course of
the study, concentrate as many experiments as pos-
sible around d0. Specifically, we aim to treat the jth
included patient at the same level we would have
estimated as being d0 had the study ended after the
inclusion of j − 1 patients.
2. CONTINUAL REASSESSMENT METHOD
The continual reassessment method (CRM), pro-
posed as a statistical design to meet the require-
ments of the type of studies described above, was
introduced by O’Quigley, Pepe and Fisher (1990).
Many developments and innovations have followed,
the basic method and variants having found a num-
ber of other potential applications. Here, we recon-
sider the original problem, expressed in statistical
terms, since it is this problem that forged the method.
In this article we consider the main theoretical ideas
and do not dwell on precise applications apart from
for illustrative purposes.
The method begins with a parameterized working
model for R(xj), denoted by ψ(xj , a), for some one-
parameter model ψ(xj , a) and a defined on the set
A. For every a, ψ(x,a) should be monotone increas-
ing in x and, for any x, ψ(x,a) should be monotone
in a. For every di there exists some ai ∈A such that
R(di) = ψ(di, ai), that is, the one-parameter model
is rich enough, at each dose, to exactly reproduce
the true probability of toxicity at that dose. There
are many choices for ψ(x,a), including the simple
Lehmann type shift model:
log{− logψ(di, a)}
(2)
= log{− logαi}+ a, i= 1, . . . , k,
where 0<α1 < · · ·<αk < 1 and −∞< a<∞, hav-
ing shown itself to work well in practice. This pa-
rameterization allows for the support of the param-
eter a to be on the whole real line and priors such
as the normal or the logistic, having heavier tails,
have been used here. The simple power model of
O’Quigley, Pepe and Fisher (1990) required that
support for the parameter a be restricted to the pos-
itive real line.
O’Quigley, Pepe and Fisher (1990) suggested that
the αi, i= 1, . . . , k, be chosen to reflect a priori as-
sumptions about the toxicity probabilities associ-
ated with each dose. Lee and Cheung (2009) pro-
vided a systematic approach to choosing the ini-
tial values for the αi, i = 1, . . . , k. Yin and Yuan
(2009) used Bayesian model averaging to combine
estimates from different sets of initial guesses at the
αi, i = 1, . . . , k. It should again be noted that the
working model is not anticipated to represent the
entire dose-toxicity curve. It suffices that the pa-
rameterized working model be flexible enough to al-
low for estimation of the dose-toxicity relationship
at and close to the MTD. This point will be de-
veloped more fully in Section 4, which summarizes
the small- and large-sample properties of the CRM.
Cheung and Chappell (2002) investigated the oper-
ational sensitivity to different model choices.
Once a model has been chosen and we have data
in the form of the set Ωj = {y1, x1, . . . , yj, xj}, the
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outcomes of the first j experiments, we obtain esti-
mates Rˆ(di) (i= 1, . . . , k) of the true unknown prob-
abilities R(di) (i= 1, . . . , k) at the k dose levels (see
below). The target dose level is that level having as-
sociated with it a probability of toxicity as close as
we can get to θ. The dose or dose level xj assigned
to the jth included patient is such that
|Rˆ(xj)− θ|
(3)
< |Rˆ(dℓ)− θ|, ℓ= 1, . . . , k;dℓ 6= xj .
This equation should be compared to (1). It trans-
lates the idea that the overall goal of the study is
also the goal for each included patient. The CRM
is then an iterative sequential design, the level cho-
sen for the (n + 1)th patient, who is hypothetical,
being also our estimate of d0. After having included
j subjects, we can calculate a posterior distribution
for a which we denote by f(a,Ωj).We then induce a
posterior distribution for ψ(di, a), i= 1, . . . , k, from
which we can obtain summary estimates of the tox-
icity probabilities at each level so that
Rˆ(di)
(4)
=
∫
a∈A
ψ(di, a)f(a,Ωj)da, i= 1, . . . , k.
Using (3) we can now decide which dose level to
allocate to the (j +1)th patient.
In the original version of the CRM, O’Quigley,
Pepe and Fisher (1990) used an alternative estimate
R˜(di) = ψ(di, µ), i = 1, . . . , k, where µ =∫
a∈A af(a,Ωj)da. This was done primarily to re-
duce the amount of calculation required, a consid-
eration of less importance today. O’Quigley, Pepe
and Fisher (1990) completed the specification of the
dose allocation algorithm by specifying a starting
dose based on a prior specification of the dose level
with probability closest to the target.
3. BAYESIAN AND LIKELIHOOD INFERENCE
In order to base inference only on the likelihood
it is necessary to have the likelihood nonmonotone
so that the estimates are not on the boundary of
the parameter space. This is accomplished by having
some initial escalation scheme until the data achieve
at least one toxicity and one nontoxicity. We can
regard the data obtained via this initial escalation
scheme as, in some sense, empirical and use them as
a data-based prior to the second part of the study.
Thus, both Bayesian and likelihood alone, can all
be put under a Bayesian heading. We use this in the
following to study different Bayesian approaches to
inference.
3.1 Likelihood-Based Dose Allocations
After the inclusion of the first j patients, the log-
arithm of the likelihood can be written as
Lj(a) =
j∑
ℓ=1
yℓ logψ(xℓ, a)
(5)
+
j∑
ℓ=1
(1− yℓ) log(1−ψ(xℓ, a)),
where any terms not involving the parameter a have
been equated to zero. We suppose that Lj(a) is max-
imized at a = aˆj . Once we have calculated aˆj we
can next obtain an estimate of the probability of
toxicity at each dose level di via Rˆ(di) = ψ(di, aˆj)
(i= 1, . . . , k). On the basis of this formula the dose
to be given to the (j + 1)th patient, xj+1, is deter-
mined. Once we have estimated a we can also calcu-
late an approximate 100(1−α)% confidence interval
for ψ(xj+1, aˆj) as (ψ
−
j , ψ
+
j ) where
ψ−j = ψ{xj+1, (aˆj + z1−α/2v(aˆj)1/2)},
ψ+j = ψ{xj+1, (aˆj − z1−α/2v(aˆj)1/2)},
where zα is the αth percentile of a standard normal
distribution and v(aˆj) is an estimate of the variance
of aˆj . For the model of (2) this turns out to be par-
ticularly simple and we can write
v−1(aˆj) =
∑
ℓ≤j,yℓ=0
ψ(xℓ, aˆj)(logαℓ)
2
/(1−ψ(xℓ, aˆj))2.
Although based on a misspecified model these inter-
vals turn out to be quite accurate, even for sample
sizes as small as 16, and thus helpful in practice
(O’Quigley, 1992).
3.2 Prior Information on the Parameter a
There are three distinct approaches which can be
used in order to establish the prior information. These
are: (1) postulate some numerically tractable and
sufficiently flexible density g(a), (2) introduce a
pseudo-data prior which indirectly will specify g(a),
and (3) use some initial escalation scheme in a two-
stage design until the first toxicity is observed. Let
us consider these three approaches more closely.
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A gamma prior for g(a) For the Lehmann shift
model, on a logarithmic scale, given that A= (0,∞),
O’Quigley, Pepe and Fisher (1990) suggested, as a
natural candidate,
g(a) = λcac−1 exp{−(λa)}/Γ(c),
Γ(c) =
∫ ∞
0
exp(−u)uc−1 du
the gamma density with scale parameter λ and shape
parameter c. The necessary steps in fitting a gamma
prior on the basis of the upper and lower points
of our prior confidence region have been described
by Martz and Waller (1982). For a relatively sim-
ple set-up involving no more than six doses and us-
ing a coding for dose (not the actual dose itself),
O’Quigley, Pepe and Fisher (1990) suggested that
the simple exponential prior for a—a special case of
the gamma prior with c and λ both equal to 1—
would be satisfactory. Some authors have appealed
to this simple exponential prior in different contexts,
or more involved set-ups, and the resulting behavior
of the method can be alarming (Moller, 1995).
Pseudo-data prior In the place of a prior expressed
as a specific parametric density function, pseudo-
data priors create observations that are weighted in
accordance with our degree of belief in their plausi-
bility. Using pseudo-data y∗ℓ , ℓ= 1, . . . ,K, the prior
g(a) is defined from
g(a) ∼= exp
[
j∑
ℓ=1
y∗ℓ logψ(xℓ, a)
(6)
+
j∑
ℓ=1
(1− y∗ℓ ) log(1−ψ(xℓ, a))
]
.
The prior “data” can be combined with the observed
data. In consequence standard and widely available
programs such as SAS or SPSS may be used directly
to calculate the posterior mode without the need for
numerical integration. The pseudo-data prior can be
used to establish our best prior guesses which will
be mirrored by the estimates of a obtained from fit-
ting the pseudo-data alone. The imprecision which
we wish to associate with this can be governed by
a weighting coefficient wj where 0 < wj < 1. This
coefficient can be independent of j and we would
usually require that wj ≤ wj−1. The posterior den-
sity is then
f(a,Ωj) =A
−1
j exp{wj log g(a)
(7)
+ (1−wj)Lj(a)},
where Aj =
∫∞
−∞
exp{wj log g(a)+ (1−wj)Lj(a)}da.
The added generality of allowing the dependence of
the weights on j would rarely be needed and, in
most practical situations, it suffices to take w as a
constant small enough so that the prior has no more
impact than deemed necessary.
Uninformative priors For the model (2), O’Quigley
(1992) suggested a normal prior having mean zero
and variance σ2, large enough to be considered non-
informative. Such a concept can be made more pre-
cise in the following way, at least for fixed sample
designs. The mean and mode of the prior are at zero
so that, should the true probabilities of toxicity ex-
actly coincide with the αi then, the more informa-
tive the prior the better we do, ultimately as the
prior tends to being degenerate, that is, σ2→ 0, we
obtain the correct level always. Taking some dis-
tance measure between the distribution of our fi-
nal recommendation and the degenerate distribution
putting all mass on the correct level, this distance
will increase as our uncertainty, as measured by σ2,
increases. The curve of this distance, as a function of
σ2, will reach an asymptotic limit, further increases
in σ2 having a vanishing influence on the error dis-
tribution of final recommendation. The smallest fi-
nite value of σ2, such that the operating characteris-
tics are sufficiently close to those obtained when σ2
is infinite (in practice very large), corresponding to
a diffuse and even improper prior, will provide the
prior with the required behavior.
An uninformative prior, in the sense that it does
not favor any particular level, can be constructed
readily in the light of the results of O’Quigley (2006)
which partition the interval [A,B] for the parameter
a into k subintervals Si (i= 1, . . . , k). If a ∈ Si, then
dose level di corresponds to the MTD. For k dose
levels we simply associate the probability mass 1/k
to each of the k subsets Si. Clearly this approach is
readily extended to the informative case by putting
priors favoring some levels more than others, either
on the basis of clinical information or simply out of
a desire to influence the operating characteristics in
some particular way. An example for the frequent
case k = 6 would be to associate the prior 0.05 with
level 1, and the values 0.19 with the other five levels.
This would result in steering us away from level 1
in favor of the other levels, unless the accumulating
data begin to weigh against our conjecture that level
1 is unlikely to be the right level.
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Fig. 1. A typical trial history using rapid early escalation; target is level 7.
Data-based prior in two-stage designs In order to
be able to maximize the log-likelihood on the inte-
rior of the parameter space we require heterogene-
ity among the responses, that is, at least one toxic
and one nontoxic response (Silvapulle, 1981). Oth-
erwise the likelihood is maximized on the boundary
of the parameter space and our estimates of R(di)
(i= 1, . . . , k) are trivially either zero, 1, or, depend-
ing on the model we are working with, may not
even be defined. In the context of “pure likelihood”-
based designs O’Quigley and Shen (1996) argued
for two-stage designs whereby an initial escalation
scheme provided the required heterogeneity. The ex-
periment can be viewed as not being fully underway
until we have some heterogeneity in the responses.
These could arise in a variety of different ways: use
of a standard Up and Down approach, use of an
initial Bayesian CRM as outlined below, or use of
a design believed to be more appropriate by the in-
vestigator. Once we have achieved heterogeneity, the
model kicks in and we continue as prescribed above
(estimation–allocation). We can also consider this
initial escalation as providing empirical data. Con-
ditional upon these data we then proceed to the sec-
ond stage. The data obtained at the end of the first
stage can be viewed as providing an empirical prior.
In this way, all the approaches can be grouped under
a Bayesian umbrella. The essential differences arise
through the different ways of specifying the prior.
Using empirical data to construct a prior as the
first stage of a two-stage design can afford us a great
deal of flexibility. The initial exploratory escalation
stage is followed by a more refined homing in on the
target. Such an idea was first proposed by Storer
(1989) in the context of the more classical Up and
Down schemes. His idea was to enable more rapid
escalation in the early part of the trial where we
may be quite far from a level at which treatment
activity could be anticipated. Moller (1995) was the
first to use this idea in the context of CRM designs.
Her idea was to allow the first stage to be based
on some variant of the usual Up and Down proce-
dures. In the context of sequential likelihood esti-
mation, the necessity of an initial stage was pointed
out by O’Quigley and Shen (1996) since the likeli-
hood equation fails to have a solution on the interior
of the parameter space unless some heterogeneity in
the responses has been observed. Their suggestion
was to work with any initial scheme, Bayesian CRM
or Up and Down, and, for any reasonable scheme,
the operating characteristics appear relatively insen-
sitive to this choice.
Here we describe an example of a two-stage design
that has been used in practice (see Figure 1). There
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were many dose levels and the first included patient
was treated at a low level. As long as we observe very
low-grade toxicities then we escalate quickly, includ-
ing only a single patient at each level. As soon as we
encounter more serious toxicities then escalation is
slowed down. Ultimately we encounter dose-limiting
toxicities at which time the second stage, based on
fitting a CRM model, comes fully into play. This is
done by integrating this information and that ob-
tained on all the earlier non-dose-limiting toxicities
to estimate the most appropriate dose level. Con-
sider the following example which uses information
on low-grade toxicities in the first stage in order to
allow rapid initial escalation (see Table 1). Specifi-
cally we define a grade severity variable S(i) to be
the average toxicity severity observed at dose level i,
that is, the sum of the severities at that level divided
by the number of patients treated at that level. The
rule is to escalate providing S(i) is less than 2. Fur-
thermore, once we have included three patients at
some level, then escalation to higher levels only oc-
curs if each cohort of three patients does not ex-
perience dose-limiting toxicity. This scheme means
that, in practice, as long as we see only toxicities of
severities coded 0 or 1, then we escalate. The first
severity coded 2 necessitates a further inclusion at
this same level and, anything other than a 0 severity
for this inclusion, would require yet a further inclu-
sion and a non-dose-limiting toxicity before being
able to escalate. This design also has the advantage
that, should we be slowed down by a severe (severity
3), albeit non-dose-limiting toxicity, we retain the
capability of picking up speed (in escalation) should
subsequent toxicities be of low degree (0 or 1). This
can be helpful in avoiding being handicapped by an
outlier or an unanticipated and possibly not drug-
related toxicity arising early in the study. Once a
dose-limiting toxicity is encountered the initial es-
calation stage is brought to a halt and the accumu-
lated data taken as our empirical prior.
Table 1
Toxicity “grades” (severities) for trial
Severity Degree of toxicity
0 No toxicity
1 Mild toxicity (non-dose-limiting)
2 Nonmild toxicity (non-dose-limiting)
3 Severe toxicity (non-dose-limiting)
4 Dose-limiting toxicity
3.3 An Illustration
An example of a two-stage design involving 16
patients was given by O’Quigley and Shen (1996).
There were six levels in the study, maximum likeli-
hood was used, and the first entered patients were
treated at the lowest level. The design was two-
stage. The true toxic probabilities wereR(d1) = 0.03,
R(d2) = 0.22, R(d3) = 0.45, R(d4) = 0.6, R(d5) = 0.8
and R(d6) = 0.95. The working model was that given
by (2) where α1 = 0.04, α2 = 0.07, α3 = 0.20, α4 =
0.35, α5 = 0.55 and α6 = 0.70. The targeted toxi-
city was given by θ = 0.2 indicating that the best
level for the MTD is given by level 2 where the true
probability of toxicity is 0.22. A grouped design was
used until heterogeneity in toxic responses was ob-
served, patients being included, as for the classical
schemes, in groups of three. The first three patients
experienced no toxicity at level 1. Escalation then
took place to level 2 and the next three patients
treated at this level did not experience any toxic-
ity either. Subsequently two out of the three pa-
tients treated at level 3 experienced toxicity. Given
this heterogeneity in the responses the maximum
likelihood estimator for a now exists and, follow-
ing a few iterations, could be seen to be equal to
0.715. We then have that Rˆ(d1) = 0.101, Rˆ(d2) =
0.149, Rˆ(d3) = 0.316, Rˆ(d4) = 0.472, Rˆ(d5) = 0.652
and Rˆ(d6) = 0.775. The 10th entered patient is then
treated at level 2 for which Rˆ(d2) = 0.149 since, from
the available estimates, this is the closest to the tar-
get θ = 0.2. The 10th included patient does not suf-
fer toxic effects and the new maximum likelihood
estimator becomes 0.759. Level 2 remains the level
with an estimated probability of toxicity closest to
the target. This same level is in fact recommended
to the remaining patients so that after 16 inclusions
the recommended MTD is level 2. The estimated
probability of toxicity at this level is 0.212 and a
90% confidence interval for this probability is esti-
mated as (0.07, 0.39).
4. LARGE-SAMPLE AND SMALL-SAMPLE
PROPERTIES
Extensive simulations (O’Quigley, Pepe and Fisher,
1990; O’Quigley and Shen, 1996; O’Quigley, 1999;
Iasonos et al., 2008), over wide choices of possi-
ble true unknown dose-toxicity situations, show the
method to behave in a mostly satisfactory way, rec-
ommending the right level or close levels in a high
percentage of situations and treating in the study
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itself a high percentage of included patients, again,
at the right level or levels close by. Cheung (2005),
O’Quigley (2006) and Lee and Cheung (2009) ob-
tained theoretical results which not only provide
some confidence in using the method but can also
provide guidance in the choice and structure of work-
ing models. Even though models are misspecified, in-
ference is still based on an estimating equation taken
from the derivative of the log-likelihood. Thus, Shen
and O’Quigley (1996) defined
In(a) =
1
n
n∑
j=1
[
yj
ψ′
ψ
{xj , a}+ (1− yj) −ψ
′
1−ψ {xj , a}
]
.
Some restrictions on ψ are needed (O’Quigley, 2006).
In particular, there must exist constants a1, . . . , ak
∈ [A,B] such that ψ(di, ai) =Ri, the function ψ sat-
isfies ψ(di,B)< θ < ψ(di,A), and there is a unique
a0 ∈ (a1, . . . , ak), ψ(d0, a0) =R(d0) = θ0. In general,
θ0 will not be equal to θ but will be as close as we
can get given the available doses. We require the es-
timating function to respect a standard condition of
estimating functions which is that
s(t, x, a) = t
ψ′
ψ
{x,a}+ (1− t) −ψ
′
1− ψ{x,a}
is continuous and strictly monotone in a. We define
I˜n(a) = n
−1
∑n
j=1 s{R(xj), xj, a}.
It is not typically the case that ψ(di, a0) =R(di)
for i= 1, . . . , k. However, at least in the vicinity of
the MTD, this will be approximately true, an idea
that can be formalized (Shen and O’Quigley, 1996)
via the definition of the set
S(a0) = {a : |ψ(d0, a)− θ|< |ψ(di, a)− θ|
(8)
for all di 6= d0}.
Shen and O’Quigley (1996) showed that convergence
follows if, for i = 1, . . . , k, ai ∈ S(a0). O’Quigley
(2006) showed that, for each 1 ≤ i ≤ k − 1, there
exists a unique constant κi such that θ−ψ(xi, κi) =
ψ(xi+1, κi)− θ > 0. The constants κi naturally give
rise to a partitioning of the parameter space [A,B].
Letting κ0 = A and κk = B, we can write the in-
terval [A,B] as a union of nonoverlapping intervals
whereby [A,B] =
⋃k
i=1[κi−1, κi). This partition is of
particular value in establishing prior distributions
which can translate immediately into priors for the
dose levels themselves. It is also of value in deriving
results concerning the coherence, stability and con-
vergence of the algorithm (Cheung and Chappell,
2002; O’Quigley, 2006).
Convergence to the MTD stems from the fact that
supa∈[A,B] |In(a)− I˜n(a)| converges almost surely to
zero (Shen and O’Quigley, 1996) and that we can re-
express I˜n(a) as a sum over the k dose levels rather
than a sum over the n subjects; in particular we
have that I˜n(a) =
∑k
i=1 πn(di)s{R(di), di, a}. Sup-
posing that the solution to the equation I˜n(a) = 0 is
a˜n and that ai is the unique solution to the equa-
tion s{R(di), di, a}= 0, then a˜n will fall into the in-
terval S1(a0). Since aˆn solves In(a) = 0, then, al-
most surely, aˆn ∈ S(a0), so that, for n sufficiently
large, xn+1 ≡ d0. Since there are only a finite num-
ber of dose levels, xn will ultimately settle at d0.
Rather than appeal to the set S(a0), which quan-
tifies the roughness of the working approximation
to the true dose-toxicity function in the vicinity of
the MTD, and which guarantees convergence to the
MTD when all of the ai belong to this set, Che-
ung (2005) used a related approach which appeals
to a more flexible—in many ways more realistic—
definition of the MTD whereby probabilities of tox-
icity within some given range are all taken to be
acceptable. Convergence can then be shown to ob-
tain without such restrictive conditions as those de-
scribed above.
4.1 Efficiency
O’Quigley (1992) proposed using θˆn = ψ(xn+1, aˆn)
to estimate the probability of toxicity at the rec-
ommended level xn+1, where aˆn is the maximum
likelihood estimate. An application of the δ-method
(Shen and O’Quigley, 1996) shows that the asymp-
totic distribution of
√
n{θˆn −R(d0)} is N{0, θ0(1−
θ0)}. The estimate then provided by CRM is fully
efficient for large samples. This is what our intu-
ition would suggest given the convergence proper-
ties of CRM. What actually takes place in finite
samples needs to be investigated on a case by case
basis. The relatively broad range of cases studied
by O’Quigley (1992) show a mean squared error for
the estimated probability of toxicity at the recom-
mended level under CRM to correspond well with
the theoretical variance for samples of size n, were
all subjects to be experimented at the correct level.
Some of the cases studied showed evidence of super-
efficiency, translating nonnegligible bias that hap-
pens to be in the right direction, while a few others
indicated efficiency losses large enough to suggest
the possibility of better performance.
A useful tool in studies of finite sample efficiency is
the idea of an optimal design. We can derive a non-
parametric optimal design (O’Quigley, Paoletti and
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Maccario, 2002) based upon no more than a mono-
tonicity assumption. Such an optimal design is not
generally available in practice but can serve as a gold
standard in theoretical studies, playing a role similar
to that of the Cramer–Rao bound. Comparisons be-
tween any suggested method and the optimal design
enable us to quantify just how much room there is
for potential improvement. Further evidence of the
efficiency of the CRM was provided by the work of
O’Quigley, Paoletti and Maccario (2002), where the
CRM is compared to the nonparametric optimal de-
sign. In the cases studied in that article and in that
of Paoletti, O’Quigley and Maccario (2004), poten-
tial for improvement is seen to be limited, with the
identification of the MTD by the two-stage CRM
design being only slightly inferior to that of the op-
timal design.
4.2 Nonidentifiability of Fully Parameterized
Models
Under the conditions outlined above we will ulti-
mately only include patients at dose level d0. Under
very much broader conditions (Shen and O’Quigley,
1996) we can guarantee convergence to some level,
not necessarily d0 but one where the probability of
toxicity will not be far removed from that at d0.
The consequence of this is that, for the most com-
mon case of a single homogeneous group of patients,
we are obliged to work with an underparameterized
model, notably a one-parameter model in the case
of a single group. Although a two-parameter model
may appear more flexible, the convergence property
of CRM means that ultimately we will not obtain
information needed to fit two parameters. Having
settled at dose level di, the only quantity we can
estimate is R(di) which can be done consistently
in light of the Glivenko–Cantelli lemma. Under our
model conditions we have that R(di) = ψ(di, ai) and
that aˆj will converge almost surely to ai. Adding
a second parameter can only overparameterize the
situation and, for example, the commonly used logis-
tic model has an infinite number of combinations of
the two parameters which lead to the same value of
R(di). A likelihood procedure can then be unstable
and may even break down, whereas a two-parameter
fully Bayesian approach (Gatsonis and Greenhouse,
1992; Whitehead and Williamson, 1998) may work
initially, although somewhat artificially, but behave
erratically as sample size increases and the struc-
tural rigidity provided by the prior gradually wanes.
This is true even when starting out at a low or the
lowest level, initially working with an Up and Down
design for early escalation, before a CRM model is
applied. Indeed, any design that ultimately concen-
trates all patients from a single group on some given
level can fit no more than a single parameter with-
out running into problems of identifiability.
5. EXTENDED CRM DESIGNS
The simple model of (2) can be extended to a class
of models denoted by ψm(xj , a) for m = 1, . . . ,M
where there are M members of the class. Take, for
example,
ψm(di, a) = α
exp(a)
mi ,
(9)
i= 1, . . . , k;m= 1, . . . ,M,
where 0 < αm1 < · · · < αmk < 1 and −∞ < a <∞,
as an immediate generalization of (2). Prior infor-
mation concerning the plausibility of each model is
catered for by π(m), m = 1, . . . ,M, where π(m) ≥
0 and where
∑
m π(m) = 1. When each model is
given the same initial weighting, then we have that
π(m) = 1/m. If the data are to be analyzed under
model m, then, after the inclusion of j patients, the
logarithm of the likelihood can be written as
Lmj(a) =
j∑
ℓ=1
yℓ logψm(xℓ, a)
(10)
+
j∑
ℓ=1
(1− yℓ) log(1− ψm(xℓ, a)),
where any terms not involving the parameter a have
been ignored. Under model m we obtain a summary
value of the parameter a, in particular the maximum
of the posterior mode and we refer to this as aˆmj .
Given the value of aˆmj under model m, we have an
estimate of the probability of toxicity at each dose
level di via Rˆ(di) = ψm(di, aˆmj) (i = 1, . . . , k). On
the basis of this formula, and having taken some
value for m, the dose to be given to the (j + 1)th
patient, xj+1, is determined. Thus, we need some
value for m and we make use of the posterior prob-
abilities of the models given the data Ωj . Denoting
these posterior probabilities by π(m|Ωj), then
π(m|Ωj)
(11)
=
π(m)
∫∞
−∞
exp{Lmj(u)}g(u)du∑M
m=1 π(m)
∫∞
−∞
exp{Lmj(u)}g(u)du
.
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The estimated values of π(m|Ωj) can help us decide
between models which have physical implications of
interest to us. As an example suppose that there
exists significant heterogeneity among the patients
and this is simplified to the case of two groups.
5.1 A Simple Heterogeneity Model
As in other types of clinical trials we are essen-
tially looking for an average effect. Patients natu-
rally differ in the way they may react to a treat-
ment and, although hampered by small samples, we
may sometimes be in a position to specifically ad-
dress the issue of patient heterogeneity. One exam-
ple occurs in patients with acute leukemia where
it has been observed that children will better tol-
erate more aggressive doses (standardized by their
weight) than adults. Likewise, heavily pretreated pa-
tients are more likely to suffer from toxic side ef-
fects than lightly pretreated patients. In such situ-
ations we may wish to carry out separate trials for
the different groups in order to identify the appro-
priate MTD for each group. Otherwise we run the
risk of recommending an “average” compromise dose
level, too toxic for a part of the population and sub-
optimal for the other. Usually, clinicians carry out
two separate trials or split a trial into two arms af-
ter encountering the first DLTs when it is believed
that there are two distinct prognostic groups. This
has the disadvantage of failing to utilize information
common to both groups. The most common situa-
tion is that of two samples where we aim to carry
out a single trial keeping in mind potential differ-
ences between the two groups. A multisample CRM
is a direct generalization although we must remain
realistic in terms of what is achievable in the light
of the available sample sizes.
Introduce a binary variable Z taking the value 0
for the first group and 1 for the second group. Sup-
pose also that we know that, for the second group,
the probability of toxicity can only be the same or
higher than the first group. For this situation con-
sider the following models:
1. Model 1: m= 1
Pr(Y = 1|di, z = 0) = ψ(di, a), i= 1, . . . , k,
Pr(Y = 1|di, z = 1) = ψ(di, a), i= 1, . . . , k,
2. Model 2: m= 2
Pr(Y = 1|di, z = 0) = ψ(di, a), i= 1, . . . , k,
Pr(Y = 1|di, z = 1) = ψ(di+1, a),
i= 1, . . . , k− 1,
Pr(Y = 1|di, z = 1) = ψ(dk, a), i= k.
If the most plausible model has m = 1, then we
conclude that there is no difference between the groups.
Ifm= 2, then we conclude that for the second group
the probability of toxicity at any level is the same as
that for a subject from the first group but treated
at one level higher. The truth will be more subtle
but since we have to treat at some level we force
this decision to be made at the modeling stage. The
idea extends, of course, to several levels, positive as
well as negative directions to the difference, and to
other factors such as treatment schedules.
5.2 Randomization and Two-Parameter Models
Suppose that j subjects are already entered in the
trial. Instead of systematically selecting the level es-
timated as being closest to the target, a different
approach would be to use the available knowledge
to randomly select a level from d1, . . . , dk according
to some given discrete distribution. This distribu-
tion does not have to be fixed in advance but can
depend on the available levels and the current es-
timate of the MTD. Let xj+1 be defined as before.
However, we will no longer allocate systematically
subject j + 1 to dose level xj+1 as before. Instead
we allocate to wj+1 where we define
wj+1 =


k∑
m=1
dm+∆I{xj+1 = dm,m < k};
Rˆ(xj+1)≤ θ
k∑
m=1
dm−∆I{xj+1 = dm,m > 1};
Rˆ(xj+1)> θ


(12)
and where ∆ is a Bernoulli(0,1) random variable
with parameter typically of value 0.5. In words, in-
stead of allocating to the level closest to Rˆ(xj+1) we
allocate, on the basis of a random mechanism, to
the level just above Rˆ(xj+1) or the level just below
Rˆ(xj+1). In the cases where Rˆ(xj+1) is lower than
the lowest available level, or higher than the highest
available level, then the allocation becomes, again,
systematic. The purpose of the design is then to be
able to sample on either side of the target. Aside
from those cases in which the lowest level appears
to be more toxic than the target or the highest level
less toxic than the target, observations will tend to
be concentrated on two levels. One of these levels
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will have an associated estimated probability below
the target while the other level will have an esti-
mated probability above the target.
An immediate consequence of forcing experimen-
tation to take place at more than a single level is
that the nonidentifiability described above changes.
It is now possible to estimate more than a single pa-
rameter, for example the rate of toxicity at, say, the
lower of the two levels as well as the rate of toxicity
at the next level up. Working with a one-parameter
model and randomizing to two levels, say dℓ and
dℓ+1, the estimate aˆ will converge to the solution of
the equation
π(dℓ)
{
Rℓ
ψ′
ψ
(dℓ, a) + (1−Rℓ) −ψ
′
1−ψ (dℓ, a)
}
,
{1− π(dℓ)}
{
Rℓ+1
ψ′
ψ
(dℓ+1, a)
+ (1−Rℓ+1) −ψ
′
1− ψ (dℓ+1, a)
}
= 0,
where π(dℓ) is the stable distribution (long-term pro-
portion) of patients included at level dℓ. Comparing
this equation with the estimating equation for the
standard case without randomization, we can see
that, unless the working model generates the obser-
vations, we will not obtain consistent estimates of
the probabilities of toxicities at the two doses of the
stable distribution. However, introducing a second
parameter into the model, one which describes the
differences between the probabilities of toxicity at
the two dose levels, we obtain consistent estimates
at these two doses of the stable distribution. To see
this it is enough to parameterize the probability of
toxicity at the current level dℓ as ψ(dℓ, a) and that
at level dℓ+1 by ψ(dℓ, a+ b). The estimates will con-
verge to the solution of
π(dℓ)
{
Rℓ
ψ′
ψ
(dℓ, a) + (1−Rℓ) −ψ
′
1−ψ (dℓ, a)
}
,
{1− π(dℓ)}
{
Rℓ+1
ψ′
ψ
(dℓ+1, a+ b)
+ (1−Rℓ+1) −ψ
′
1−ψ (dℓ+1, a+ b)
}
= 0,
for which each term separately can be then accom-
modated within the framework describing consis-
tency given above. In practice we would use a model
such as the logistic where
ψ(dk, a, b) =
exp(aαk + b)
1 + exp(aαk + b)
,
which, once settling takes place, is then a saturated
model.
6. RELATED DESIGNS
There have been many suggestions in the litera-
ture for possible modifications of the basic design.
Also, some apparently alternative designs turn out
to be equivalent to the basic design. In this section
we consider some of these designs.
6.1 Escalation with Underdose/Overdose
Control
Babb, Rogatko and Zacks (1998) argued that the
main ethical concern was not so much putting each
patient at a dose estimated to be the closest to
the MTD but rather putting each patient at a dose
for which the probability of it being too great was
minimized. The difference may be subtle but would
be a basis for useful, and important, discussions
with the clinicians involved. These discussions help
make explicit the goals, both in terms of final rec-
ommendation and for those patients included in the
study. There may be situations where a parallel con-
cern might focus on the underdosing rather than
the overdosing. For an approach based on the CRM
we would simply modify the definition of the dose
level “closest to the target” to be asymmetric. Pos-
itive distances could be magnified relative to nega-
tive ones resulting in a tendency to assign below the
MTD rather than above it.
Babb, Rogatko and Zacks (1998) approached the
problem differently by focusing on the posterior dis-
tribution of the MTD and suggesting a loss function
that penalizes overdosing to a greater degree than
underdosing. Tighiouart, Rogatko and Babb (2005)
developed the idea further, investigating a number
of prior distributions. Despite this change in empha-
sis, there is no fundamental difference between these
approaches and the CRM, aside from the making
use of a particular distance measure. The methods
of Babb, Rogatko and Zacks (1998) and Tighiouart,
Rogatko and Babb (2005) allow for continuous dose
levels. Although the CRM is most frequently ap-
plied in cases with a fixed set of dose levels, it can
be adapted to allocate patients on dose levels other
than the fixed set of doses.
6.2 ADEPT and Two-Parameter CRM
O’Quigley, Pepe and Fisher (1990) studied two-
parameter CRM models based on the logistic dis-
tribution. For large samples the parameters are not
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identifiable and we may expect that this could lead
to unstable or undesirable operating characteristics.
For small to moderate finite samples the behavior
can be studied on a case by case basis. Even when
the two-parameter model correctly generated the
observations, the simulations of O’Quigley, Pepe and
Fisher indicated that the one-parameter CRMwould
work better for sample sizes up to around 25.
Whitehead and Brunier (1995) suggested working
with the two-parameter logistic model and using a
pseudo-data prior. This has been put together as a
software package and is called ADEPT. The term
ADEPT is used to describe either the software itself
or the approach which would be equivalent to a two-
parameter CRM with a data-based prior. Gerke and
Siedentop (2008) argued that ADEPT is to be pre-
ferred to standard CRM in terms of accuracy of rec-
ommendation. This conclusion was based on a study
of three, rather particular, situations in which the
target dose lies exactly at the midpoint between two
of the available doses. They define the lower of these
two doses as being the MTD. Gerke and Siedentop’s
definition of the MTD is not the usual one which,
had it been used in their simulations, would have
resulted in the very opposite conclusion. The usual
one, and that used in O’Quigley, Pepe and Fisher,
is the dose which is the closest to the target. Should
two doses be equidistant from the target then, logi-
cally, either one could be considered to be the MTD.
This observation alone would completely reverse the
findings of Gerke and Siedentop (Shu and O’Quigley,
2008).
The ADEPT program leans more formally on
Bayesian decision procedures which, it is argued
(Whitehead and Brunier, 1995), represent a general-
ization of the CRM since, instead of basing sequen-
tial patient allocation on the anticipated gain for the
next included patient or group of patients, allocation
could be based on the gain for the variance of esti-
mators. In the case of more than one parameter we
could use different combinations of the individual
variances and covariances, in particular the deter-
minant of the information matrix. Whitehead and
Brunier argued that “gain functions can be devised
from the point of view of the investigator (accuracy
for future patients) or from the point of view of the
next included patient, as in the CRM. Weighted av-
erages of these two possibilities can be used to form
compromise procedures.”
However, under current guidelines, it is not pos-
sible to use a procedure which sacrifices the point
of view of the current patient to that of future pa-
tients. It is only future patients who may benefit
from improved precision (the point of view of the
investigator) and, although, in medical experimen-
tation, arguments have been and will continue to be
put in such a direction, such logic is not currently
considered acceptable. Experimentation on an indi-
vidual patient can only be justified if it can be ar-
gued that the driving goal is the benefit of that same
patient. Basing allocation on anything other than
patient gain, and, in particular, the gain for future
patients, would be a violation of the usual ethical
criteria in force in this area. In practice, only patient
gain is used, and so ADEPT is essentially the same
as two-parameter CRM. In animal experimentation
or in experimentation in healthy volunteers, where
severe side effects are considered very unlikely, a case
could be built for using other gain functions.
6.3 Curve-Free Designs
Rather than appeal to a working model ψ(x,a)
and have a follow some distribution, we can employ
a multivariate distribution of dimension k and con-
sider the ordered probabilities at the k levels to be
the quantities of interest. Prior median or mean val-
ues for the distribution of R(di), the probability of
toxicity at dose di, are provided by the clinician.
We then work with a multivariate law that is flexi-
ble enough to allow reasonable operating character-
istics, escalating quickly enough in the absence of
observed toxicities and not being unstable or overre-
acting to toxicities that occur. Gasparini and Eisele
(2000) argued in favor of experimenting this way.
They suggested working with a product of beta pri-
ors (PBP) upon reparameterizing whereby
θ1 = 1−R(d1),
θi =
1−R(di)
1−R(di−1) , i= 2, . . . , k,
and then letting the θi (i = 1, . . . , k) have indepen-
dent beta distributions. Since R(di) = 1− θ1θ2 · · ·θi
the monotonicity constraint is respected. The distri-
bution of a product of beta distributions is complex
but the authors argue that we can approximate this
well by taking the product itself to be beta. We then
fit such a beta using the first two moments from the
product, easily achieved under the condition of inde-
pendence of the θi. Gasparini and Eisele (2000) pro-
vided some guidelines for setting up the prior for this
multivariate law based on consideration of operating
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characteristics. O’Quigley (2002b) demonstrated an
equivalence between a curve-free design and a CRM
design in that, given a particular specification of a
curve-free design, there exists an equivalent speci-
fication of a CRM design. This is also true in the
other direction. By equivalent we mean that all op-
erational characteristics are the same. However, this
still remains only an existence result and it is not yet
known how to actually find the equivalent designs.
Cheung (2002) noted that in cases where low toxic-
ity percentiles are targeted, the use of the nonpara-
metric approach with a vague prior can lead to dose
allocation that tends to be confined to suboptimal
levels. Cheung (2002) exploited the connection with
the CRM to suggest informative priors that can help
alleviate this problem.
Whitehead et al. (2010) suggested an approach
in which the probabilities of toxicity at each dose,
rather than belonging to some continuum, are only
allowed to belong to a small discrete set. In practice,
we do not need to distinguish a probability of tox-
icity of 0.32 from a probability of 0.34. They could
be considered the same, or, in some sense at least,
equivalent. The idea is not unrelated to the idea
of Cheung and Chappell (2002) on indifference in-
tervals. Performance of Whitehead and colleague’s
method is comparable to the CRM.
7. IDENTIFYING THE MOST SUCCESSFUL
DOSE (MSD)
In the context of dose finding in HIV, O’Quigley,
Hughes and Fenton (2001) considered the problem of
finding the dose which maximizes the overall prob-
ability of success. Here, failure is either a toxicity
(in the HIV context, mostly an inability to main-
tain treatment) or an unacceptably low therapeu-
tic response. Zohar and O’Quigley (2006a) made a
slight modification to the approach to better accom-
modate the cancer setting. We take Y and V to be
binary random variables (0,1) where Y = 1 denotes
a toxicity, Y = 0 a nontoxicity, V = 1 a response,
and V = 0 a nonresponse. As before, the probability
of toxicity at the dose level Xj = xj is defined by
R(xj) = Pr(Yj = 1|Xj = xj).
The probability of response given no toxicity at dose
level Xj = xj is defined by
Q(xj) = Pr(Vj = 1|Xj = xj, Yj = 0),
so that P (di) =Q(di){1−R(di)} is the probability
of success. A successful trial would identify the dose
level l such that P (dl)>P (di) (for all i where i 6= l).
Zohar and O’Quigley (2006b) called this dose the
most successful dose and our purpose in this kind of
study is, rather than find the MTD, to find the MSD.
The relationship between toxicity and dose (xj) and
the relationship between response given no toxicity
and dose can be modeled through the use of two one-
parameter models. Whereas R(di) and Q(di) refer
to exact, usually unknown, probabilities, the model-
based equivalents of these, ψ and φ, respectively, are
only working approximations given by
R(di)≈ ψ(di, a) = αexpai ;
Q(di)≈ φ(di, b) = βexp bi ,
where 0<α1 < · · ·< αk < 1, −∞< a<∞, 0< β1 <
· · ·< βk < 1 and −∞< b <∞. For each dose, there
exist unique values of a and b such that the approx-
imation becomes an equality at that dose, but not
necessarily exact at the other doses. After the in-
clusion of j patients, R(di), Q(di), and P (di) are
estimated by
Rˆ(di) = ψ(di, aˆj); Qˆ(di) = φ(di, bˆj);
Pˆ = φ(di, bˆj){1−ψ(di, aˆj)},
where aˆj and bˆj maximize the log-likelihood (see
O’Quigley, Hughes and Fenton, 2001).
8. CONCLUSIONS
More fully Bayesian approaches in a decision mak-
ing context, and not simply making use of Bayesian
estimators, have been suggested for use in the con-
text of Phase I trial designs. These can be more in
the Bayesian spirit of inference, in which we quan-
tify prior information, observed from outside the
trial as well as that solicited from clinicians and/or
pharmacologists. Decisions are made more formally
using tools from decision theory. Any prior informa-
tion can subsequently be incorporated via the Bayes
formula into a posterior density that also involves
the actual current observations. Given the typically
small sample sizes often used, a fully Bayesian ap-
proach has some appeal in that we would not wish
to waste any relevant information at hand. Unlike
the set-up described by O’Quigley, Pepe and Fisher
(1990), we could also work with informative priors.
Gatsonis and Greenhouse (1992) considered two-
parameter probit and logit models for dose response
and studied the effect of different prior distributions.
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Whitehead and Williamson (1998) carried out sim-
ilar studies but with attention focusing on logistic
models and beta priors. Whitehead and Williamson
(1998) worked with some of the more classical no-
tions from optimal design for choosing the dose lev-
els in a bid to establish whether much is lost by us-
ing suboptimal designs. O’Quigley, Pepe and Fisher
(1990) ruled out criteria based on optimal design due
to the ethical criterion of the need to attempt to as-
sign the sequentially included patients at the most
appropriate level for the patient. This same point
was also emphasized by Whitehead and Williamson
(1998). Certain contexts, however, may allow the use
of more formal optimal procedures.
For certain problems we may have good knowl-
edge about some aspect of the problem and poor
knowledge on the others. The overall dose-toxicity
curve may be very poorly known but, if this were
to be given for, say, one group, then we would have
quite strong knowledge of the dose-toxicity curve for
another group. Uninformative Bayes or maximum
likelihood would then seem appropriate overall al-
though we would still like to use information that we
have, an example being the case of a group weak-
ened by extensive prior therapy and thereby very
likely to have a level strictly less than that for the
other group. Careful parameterization would enable
this information to be included as a constraint. How-
ever, rather than work with a rigid and unmodifiable
constraint, a Bayesian approach would allow us to
specify the anticipated direction with high proba-
bility while enabling the accumulating data to over-
ride this assumed direction if the two run into se-
rious conflict. Exactly the same idea could be used
in a case where we believe there may be group het-
erogeneity but that it be very unlikely the correct
MTDs differ by more than a single level. This is es-
pecially likely to be of relevance in situations where
a defining prognostic variable, say the amount of
prior treatment, is not very sharp so that group
classifications may be subject to some error. If the
resulting MTDs do differ we would not expect the
difference to be very great. Incorporating such in-
formation into the design will improve efficiency.
Stochastic approximation, which is an algorithm
for finding the root of an unknown regression equa-
tion, can be shown, under certain conditions, to be
equivalent to recursive inversion of a linear model
(Wu, 1985, 1986; Cheung and Elkind, 2010). In the
light of those results, the CRM, in its basic form,
could then be viewed as stochastic approximation
leaning upon a particular dose-response model rather
than a linear one. However, this characterization of
the methodology is less fundamental than two oth-
ers: (1) use of an underparameterized model and (2)
restriction of the available doses to a limited finite
set.
The second of the above characterizations implies
the necessity for the first (see Section 4.2). Consis-
tency of stochastic approximation fails in the setting
where we have a limited set of available responses
(doses) and can only be achieved under conditions
analogous to those outlined in this article (Shen
and O’Quigley, 2000). Other algorithms similar to
stochastic approximation (adaptive designs) rely on
probabilistic rules to identify some percentile (dose)
from an unknown distribution. Wu’s (1985, 1986)
findings suggest that there is usually some implicit
model behind the algorithm.
The CRM makes implicit models explicit ones;
underparameterized, and therefore misspecified, but
sufficiently flexible to obtain accurate estimates lo-
cally although not reliable at points removed from
those at which the bulk of experimentation takes
place. The model, being explicit, readily enables ex-
tension and generalization. The two group case, in-
corporation of randomization about the target or
the inclusion of partial prior information are, at least
conceptually, relatively straightforward tasks. The
framework is then in place to investigate other as-
pects of dose-finding designs such as multigrade out-
comes or the ability to exploit information on within-
subject escalation. As for any method, there is al-
ways room for improvement, although the results on
optimality suggest that, for the basic problem, this
room is not great. It is likely to be more fruitful to
focus our attention on more involved problems such
as continuous outcomes, subject heterogeneity, com-
bined efficacy-toxicity studies, and studies involving
escalation of two or more components.
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